TORONTO, July 22, 2016—As the Alzheimer’s Association International Conference (AAIC) kicks off, UsAgainstAlzheimer’s (UsA2)  will be an active participant across a number of fronts, spanning research, clinical trial recruitment, minimizing disparities and improving caregiver support, adding its voice among international investigators, clinicians and care providers to advance science and see critical dementia breakthroughs come to fruition.

The following provides a snapshot of UsA2’s activities during the week-long conference: 

• Recent findings from a pipeline analysis conducted by ResearchersAgainstAlzheimer’s (RA2), a UsA2 network, showed that there are currently 17 Alzheimer’s drugs in Phase 3 clinical trials on course to launch in the next five years. During the conference, RA2 will be presenting its translation of its pipeline analysis for use in Japan.
• WomenAgainstAlzheimer’s, a UsA2 network, will be co-hosting the Global Women’s Brain Health Alliance Roundtable and Luncheon to advance the global women’s movement. The event will feature the launch of Phase II of the Health-ebrain study.
• The UsAgainstAlzheimer’s incubated clinical trial re-engineering project – the Global Alzheimer’s Platform – will be mounting three major events and will announce the first-ever meeting with more than 50 clinical trial sites interested in joining a new high-performance clinical trial network for Alzheimer's trials.
• The UsAgainstAlzheimer’s patient-powered industry coalition – the Global CEO Initiative on Alzheimer’s – will be briefing industry members on exciting developments in regulatory and market access issues.
• The UsAgainstAlzheimer’s 21^st Century Brain Trust coalition will be making an important announcement regarding an innovative mobile technology for caregiver health.  
• UsAgainstAlzheimer’s Co-Founder and Chairman George Vradenburg will attend the World Dementia Council meeting scheduled during AAIC (July 28-29).

Given this momentum and recent steps to increase Alzheimer’s funding in the United States, UsA2 will set a tone of optimism at the conference, focusing on the need to continue prioritizing research and funding globally, preparing the workforce to administer new therapies, conveying to payers the value of increasing access to the broadest number of patients possible and advocating for the needs of caregivers.

“We are finally engaged in the battle against Alzheimer’s.  And we are engaged across all fronts – from policy to research to clinical trial re-engineering to market access to physician readiness. It’s not if, it’s when, we’ll have innovative medicines for Alzheimer’s, so it’s important that the breadth of all of this work include the voices of both caregivers and patients, the very people whom we are seeking to serve,” said George Vradenburg, UsAgainstAlzheimer’s Founder and Chairman.

UsAgainstAlzheimer’s leadership (see below) with be available for interviews onsite throughout the conference. Please contact Tim Tassa at [email protected] if you would like to schedule an interview.

• George Vradenburg, Co-Founder and Chairman, UsAgainstAlzheimer’s
• Trish Vradenburg, Co-Founder and Co-Chair, UsAgainstAlzheimer’s
• Meryl Comer, UsA2 Board Member; Founder, WomenAgainstAlzheimer’s; President, Geoffrey Beene Foundation Alzheimer's Initiative
• Jill Lesser, WomenAgainstAlzheimer’s, President
• Drew Holzapfel, ResearchersAgainstAlzheimer’s, Director
• Daisy Duarte, LatinosAgainstAlzheimer’s Patient and Caregiver Advocate

###

UsAgainstAlzheimer’s (UsA2) is an innovative non-profit organization demanding – and delivering – a solution to Alzheimer’s. Driven by the suffering of millions of families, UsAgainstAlzheimer’s presses for greater urgency from government, industry and the scientific community in the quest for an Alzheimer's cure – accomplishing this through effective leadership, collaborative advocacy, and strategic investments.

Founded in 2010, UsAgainstAlzheimer’s has worked across sectors to: (1) secure the national goal of preventing and effectively treating Alzheimer’s by 2025 and help secure nearly $500 million in additional public funding for Alzheimer’s research over the past few years; (2) drive global efforts that resulted in the leaders of the world’s most powerful nations, the G7 group, to embrace a similar 2025 goal and to call for greater levels of research investment and collaboration; and (3) forge industry commitments to improve efficiencies for an expedited drug discovery and approval process.

Contact: Tim Tassa

Phone: 202-263-2580

Email: [email protected]